Nature Communications (Jan 2018)
NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus
- Hans D. Brightbill,
- Eric Suto,
- Nicole Blaquiere,
- Nandhini Ramamoorthi,
- Swathi Sujatha-Bhaskar,
- Emily B. Gogol,
- Georgette M. Castanedo,
- Benjamin T. Jackson,
- Youngsu C. Kwon,
- Susan Haller,
- Justin Lesch,
- Karin Bents,
- Christine Everett,
- Pawan Bir Kohli,
- Sandra Linge,
- Laura Christian,
- Kathy Barrett,
- Allan Jaochico,
- Leonid M. Berezhkovskiy,
- Peter W. Fan,
- Zora Modrusan,
- Kelli Veliz,
- Michael J. Townsend,
- Jason DeVoss,
- Adam R. Johnson,
- Robert Godemann,
- Wyne P. Lee,
- Cary D. Austin,
- Brent S. McKenzie,
- Jason A. Hackney,
- James J. Crawford,
- Steven T. Staben,
- Moulay H. Alaoui Ismaili,
- Lawren C. Wu,
- Nico Ghilardi
Affiliations
- Hans D. Brightbill
- Department of Immunology Discovery, Genentech
- Eric Suto
- Department of Translational Immunology, Genentech
- Nicole Blaquiere
- Department of Discovery Chemistry, Genentech
- Nandhini Ramamoorthi
- Department of Biomarker Discovery, Genentech
- Swathi Sujatha-Bhaskar
- Department of Immunology Discovery, Genentech
- Emily B. Gogol
- Department of Immunology Discovery, Genentech
- Georgette M. Castanedo
- Department of Discovery Chemistry, Genentech
- Benjamin T. Jackson
- Department of Immunology Discovery, Genentech
- Youngsu C. Kwon
- Department of Translational Immunology, Genentech
- Susan Haller
- Department of Pathology, Genentech
- Justin Lesch
- Department of Translational Immunology, Genentech
- Karin Bents
- Evotec, Inc.
- Christine Everett
- Department of Biochemical and Cellular Pharmacology, Genentech
- Pawan Bir Kohli
- Department of Biochemical and Cellular Pharmacology, Genentech
- Sandra Linge
- Evotec, Inc.
- Laura Christian
- Department of Immunology Discovery, Genentech
- Kathy Barrett
- Department of Biochemical and Cellular Pharmacology, Genentech
- Allan Jaochico
- Department of Drug Metabolism and Pharmacokinetics, Genentech
- Leonid M. Berezhkovskiy
- Department of Drug Metabolism and Pharmacokinetics, Genentech
- Peter W. Fan
- Department of Drug Metabolism and Pharmacokinetics, Genentech
- Zora Modrusan
- Department of Molecular Biology, Genentech
- Kelli Veliz
- Department of Laboratory Animal Resources, Genentech
- Michael J. Townsend
- Department of Biomarker Discovery, Genentech
- Jason DeVoss
- Department of Translational Immunology, Genentech
- Adam R. Johnson
- Department of Biochemical and Cellular Pharmacology, Genentech
- Robert Godemann
- Evotec, Inc.
- Wyne P. Lee
- Department of Translational Immunology, Genentech
- Cary D. Austin
- Department of Pathology, Genentech
- Brent S. McKenzie
- Department of Translational Immunology, Genentech
- Jason A. Hackney
- Department of Bioinformatics and Computational Biology, Genentech
- James J. Crawford
- Department of Discovery Chemistry, Genentech
- Steven T. Staben
- Department of Discovery Chemistry, Genentech
- Moulay H. Alaoui Ismaili
- Department of Biochemical and Cellular Pharmacology, Genentech
- Lawren C. Wu
- Department of Immunology Discovery, Genentech
- Nico Ghilardi
- Department of Immunology Discovery, Genentech
- DOI
- https://doi.org/10.1038/s41467-017-02672-0
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 14
Abstract
Clinical trials of BAFF blockade with belimumab have shown partial efficacy for the treatment of systemic lupus erythematosus (SLE), so other therapeutic options are required. Here, the authors present a new small molecule inhibitor that targets NIK with a similar efficacy to BAFF inhibition in two mouse models of SLE.
